18 0 2 0 2 B-lower_bound
years 3 8 3 8 I-lower_bound
old 9 12 9 12 O
or 13 15 13 15 O
older 16 21 16 21 O

Acute 0 5 22 27 B-chronic_disease
infections 6 16 28 38 I-chronic_disease
identified 17 27 39 49 O
during 28 34 50 56 O
screening 35 44 57 66 O
that 45 49 67 71 O
require 50 57 72 79 O
antibiotics 58 69 80 91 B-treatment

Chronic 0 7 92 99 O
infections 8 18 100 110 O
such 19 23 111 115 O
as 24 26 116 118 O
hepatitis 27 36 119 128 B-chronic_disease
B 37 38 129 130 I-chronic_disease
, 38 39 130 131 O
hepatitis 40 49 132 141 B-chronic_disease
C 50 51 142 143 I-chronic_disease
, 51 52 143 144 O
HIV 53 56 145 148 B-chronic_disease
or 57 59 149 151 O
Tuberculosis 60 72 152 164 B-chronic_disease

Current 0 7 165 172 O
or 8 10 173 175 O
previous 11 19 176 184 O
diagnosis 20 29 185 194 O
of 30 32 195 197 O
malignant 33 42 198 207 B-cancer
disease 43 50 208 215 I-cancer

Current 0 7 216 223 O
use 8 11 224 227 O
( 12 13 228 229 O
within 13 19 229 235 O
3 20 21 236 237 B-upper_bound
months 22 28 238 244 I-upper_bound
) 28 29 244 245 O
of 30 32 246 248 O
tocilizumab 33 44 249 260 B-treatment
, 44 45 260 261 O
rituximab 46 55 262 271 B-treatment
, 55 56 271 272 O
belimumab 57 66 273 282 B-treatment
, 66 67 282 283 O
intravenous 68 79 284 295 B-treatment
gammaglobulin 80 93 296 309 I-treatment
or 94 96 310 312 O
other 97 102 313 318 O
biologic 103 111 319 327 B-treatment

Current 0 7 328 335 O
use 8 11 336 339 O
of 12 14 340 342 O
cyclophosphamide 15 31 343 359 B-treatment
or 32 34 360 362 O
having 35 41 363 369 O
received 42 50 370 378 O
cyclophosphamide 51 67 379 395 O
within 68 74 396 402 O
the 75 78 403 406 O
last 79 83 407 411 O
year 84 88 412 416 O

Diagnosis 0 9 417 426 O
of 10 12 427 429 O
DM 13 15 430 432 B-chronic_disease
or 16 18 433 435 O
meeting 19 26 436 443 O
DM 27 29 444 446 O
criteria 30 38 447 455 O
at 39 41 456 458 O
screening 42 51 459 468 O
visit 52 57 469 474 O
, 57 58 474 475 O
as 59 61 476 478 O
established 62 73 479 490 O
by 74 76 491 493 O
new 77 80 494 497 O
classification 81 95 498 512 O
criteria 96 104 513 521 O

Expected 0 8 522 530 O
need 9 13 531 535 O
for 14 17 536 539 O
major 18 23 540 545 B-treatment
surgery 24 31 546 553 I-treatment
during 32 38 554 560 O
trial 39 44 561 566 O

History 0 7 567 574 O
of 8 10 575 577 O
poor 11 15 578 582 O
compliance 16 26 583 593 O
with 27 31 594 598 O
medical 32 39 599 606 O
care 40 44 607 611 O
, 44 45 611 612 O
study 46 51 613 618 O
visits 52 58 619 625 O
and/or 59 65 626 632 O
medication 66 76 633 643 B-treatment
use 77 80 644 647 O

If 0 2 648 650 O
the 3 6 651 654 O
T 7 8 655 656 B-clinical_variable
score 9 14 657 662 I-clinical_variable
is 15 17 663 665 O
worse 18 23 666 671 O
than 24 28 672 676 O
-2.5 29 33 677 681 B-lower_bound
, 33 34 681 682 O
they 35 39 683 687 O
will 40 44 688 692 O
be 45 47 693 695 O
excluded 48 56 696 704 O
from 57 61 705 709 O
participating 62 75 710 723 O
unless 76 82 724 730 O
the 83 86 731 734 O
subject 87 94 735 742 O
is 95 97 743 745 O
willing 98 105 746 753 O
to 106 108 754 756 O
begin 109 114 757 762 O
appropriate 115 126 763 774 O
treatment 127 136 775 784 B-treatment
for 137 140 785 788 O
osteoporosis 141 153 789 801 B-chronic_disease
by 154 156 802 804 O
Visit 157 162 805 810 O
Day 163 166 811 814 O
1 167 168 815 816 O

Known 0 5 817 822 O
hypersensitivity 6 22 823 839 O
to 23 25 840 842 O
TZDs 26 30 843 847 B-allergy_name

Known 0 5 848 853 O
latex 6 11 854 859 O
allergy 12 19 860 867 O
for 20 23 868 871 O
EndoPAT 24 31 872 879 B-allergy_name
test 32 36 880 884 I-allergy_name

Meet 0 4 885 889 O
revised 5 12 890 897 O
ACR 13 16 898 901 O
criteria 17 25 902 910 O
and 26 29 911 914 O
2012 30 34 915 919 B-upper_bound
SLICC 35 40 920 925 O
criteria 41 49 926 934 O
for 50 53 935 938 O
SLE 54 57 939 942 O
and 58 61 943 946 O
have 62 66 947 951 O
: 66 67 951 952 O
a 68 69 953 954 O
) 69 70 954 955 O
a 71 72 956 957 O
baseline 73 81 958 966 B-clinical_variable
SLEDAI-2 82 90 967 975 I-clinical_variable
K 90 91 975 976 I-clinical_variable
greater 92 99 977 984 O
than 100 104 985 989 O
or 105 107 990 992 O
equal 108 113 993 998 O
to 114 116 999 1001 O
4 117 118 1002 1003 B-lower_bound
and 119 122 1004 1007 O
< 123 124 1008 1009 O
20 124 126 1009 1011 O
or 127 129 1012 1014 O
a 130 131 1015 1016 O
clinical 132 140 1017 1025 B-clinical_variable
SLEDAI-2 141 149 1026 1034 I-clinical_variable
K 149 150 1034 1035 I-clinical_variable
greater 151 158 1036 1043 O
than 159 163 1044 1048 O
or 164 166 1049 1051 O
equal 167 172 1052 1057 O
to 173 175 1058 1060 O
2 176 177 1061 1062 O
( 178 179 1063 1064 O
not 179 182 1064 1067 O
considering 183 194 1068 1079 O
anti 195 199 1080 1084 O
- 199 200 1084 1085 O
dsDNA 200 205 1085 1090 O
or 206 208 1091 1093 O
complement 209 219 1094 1104 O
levels 220 226 1105 1111 O
) 226 227 1111 1112 O
and 228 231 1113 1116 O
b 232 233 1117 1118 O
) 233 234 1118 1119 O
lack 235 239 1120 1124 O
of 240 242 1125 1127 O
BILAG 243 248 1128 1133 O
A 249 250 1134 1135 O
flare 251 256 1136 1141 O
at 257 259 1142 1144 O
baseline 260 268 1145 1153 O

Patients 0 8 1154 1162 O
with 9 13 1163 1167 O
active 14 20 1168 1174 O
lupus 21 26 1175 1180 B-chronic_disease
nephritis 27 36 1181 1190 I-chronic_disease
or 37 39 1191 1193 O
active 40 46 1194 1200 O
CNS 47 50 1201 1204 B-chronic_disease
lupus 51 56 1205 1210 I-chronic_disease
at 57 59 1211 1213 O
baseline 60 68 1214 1222 O
even 69 73 1223 1227 O
if 74 76 1228 1230 O
SLEDAI-2 77 85 1231 1239 B-clinical_variable
K 85 86 1239 1240 I-clinical_variable
< 87 88 1241 1242 O
20 88 90 1242 1244 B-upper_bound
. 90 91 1244 1245 O
Active 92 98 1246 1252 O
disease 99 106 1253 1260 O
will 107 111 1261 1265 O
be 112 114 1266 1268 O
considered 115 125 1269 1279 O
as 126 128 1280 1282 O
CNS 129 132 1283 1286 O
or 133 135 1287 1289 O
renal 136 141 1290 1295 B-chronic_disease
disease 142 149 1296 1303 I-chronic_disease
that 150 154 1304 1308 O
require 155 162 1309 1316 O
aggressive 163 173 1317 1327 B-treatment
immunosuppression 174 191 1328 1345 I-treatment
. 191 192 1345 1346 O
Active 193 199 1347 1353 O
CNS 200 203 1354 1357 B-chronic_disease
disease 204 211 1358 1365 I-chronic_disease
will 212 216 1366 1370 O
be 217 219 1371 1373 O
diagnosed 220 229 1374 1383 O
based 230 235 1384 1389 O
on 236 238 1390 1392 O
clinical 239 247 1393 1401 O
presentation 248 260 1402 1414 O
and 261 264 1415 1418 O
physical 265 273 1419 1427 O
exam 274 278 1428 1432 O
, 278 279 1432 1433 O
exclusion 280 289 1434 1443 O
of 290 292 1444 1446 O
other 293 298 1447 1452 O
conditions 299 309 1453 1463 O
that 310 314 1464 1468 O
could 315 320 1469 1474 O
explain 321 328 1475 1482 O
symptomatology 329 343 1483 1497 O
and 344 347 1498 1501 O
, 347 348 1501 1502 O
when 349 353 1503 1507 O
warranted 354 363 1508 1517 O
, 363 364 1517 1518 O
ancillary 365 374 1519 1528 B-treatment
tests 375 380 1529 1534 I-treatment
( 381 382 1535 1536 O
imaging 382 389 1536 1543 O
) 389 390 1543 1544 O
that 391 395 1545 1549 O
support 396 403 1550 1557 O
the 404 407 1558 1561 O
diagnosis 408 417 1562 1571 O

Patients 0 8 1572 1580 O
with 9 13 1581 1585 O
current 14 21 1586 1593 O
heart 22 27 1594 1599 B-chronic_disease
failure 28 35 1600 1607 I-chronic_disease
( 36 37 1608 1609 O
NYHA 37 41 1609 1613 B-chronic_disease
class 42 47 1614 1619 I-chronic_disease
II 48 50 1620 1622 I-chronic_disease
, 50 51 1622 1623 O
III 52 55 1624 1627 B-chronic_disease
or 56 58 1628 1630 O
IV 59 61 1631 1633 B-chronic_disease
) 61 62 1633 1634 O
and/or 63 69 1635 1641 O
a 70 71 1642 1643 O
left 72 76 1644 1648 B-clinical_variable
ventricular 77 88 1649 1660 I-clinical_variable
ejection 89 97 1661 1669 I-clinical_variable
fraction 98 106 1670 1678 I-clinical_variable
of 107 109 1679 1681 O
< 110 111 1682 1683 O
45 111 113 1683 1685 B-upper_bound
% 113 114 1685 1686 I-upper_bound
by 115 117 1687 1689 O
echocardiogram 118 132 1690 1704 O
at 133 135 1705 1707 O
screening 136 145 1708 1717 O

Patients 0 8 1718 1726 O
with 9 13 1727 1731 O
diabetes 14 22 1732 1740 B-chronic_disease
are 23 26 1741 1744 O
excluded 27 35 1745 1753 O
because 36 43 1754 1761 O
diabetes 44 52 1762 1770 O
by 53 55 1771 1773 O
itself 56 62 1774 1780 O
will 63 67 1781 1785 O
induce 68 74 1786 1792 O
profound 75 83 1793 1801 O
changes 84 91 1802 1809 O
in 92 94 1810 1812 O
endothelial 95 106 1813 1824 O
function 107 115 1825 1833 O
and 116 119 1834 1837 O
we 120 122 1838 1840 O
want 123 127 1841 1845 O
to 128 130 1846 1848 O
assess 131 137 1849 1855 O
the 138 141 1856 1859 O
effects 142 149 1860 1867 O
of 150 152 1868 1870 O
PPAR 153 157 1871 1875 B-treatment
agonists 158 166 1876 1884 I-treatment
in 167 169 1885 1887 O
vascular 170 178 1888 1896 O
risk 179 183 1897 1901 O
beyond 184 190 1902 1908 O
changes 191 198 1909 1916 O
in 199 201 1917 1919 O
insulin 202 209 1920 1927 O
resistance 210 220 1928 1938 O

Patients 0 8 1939 1947 O
with 9 13 1948 1952 O
severe 14 20 1953 1959 O
Raynaud 21 28 1960 1967 B-chronic_disease
's 28 30 1967 1969 I-chronic_disease
phenomenon 31 41 1970 1980 I-chronic_disease
, 41 42 1980 1981 O
history 43 50 1982 1989 O
of 51 53 1990 1992 O
finger 54 60 1993 1999 B-chronic_disease
ulcers 61 67 2000 2006 I-chronic_disease
or 68 70 2007 2009 O
finger 71 77 2010 2016 B-treatment
gangrene 78 86 2017 2025 I-treatment
will 87 91 2026 2030 O
not 92 95 2031 2034 O
undergo 96 103 2035 2042 O
Endopat 104 111 2043 2050 O
testing 112 119 2051 2058 O

Patients 0 8 2059 2067 O
with 9 13 2068 2072 O
severe 14 20 2073 2079 O
SLE 21 24 2080 2083 B-chronic_disease
at 25 27 2084 2086 O
baseline 28 36 2087 2095 O
, 36 37 2095 2096 O
as 38 40 2097 2099 O
quantified 41 51 2100 2110 O
as 52 54 2111 2113 O
SLEDAI-2 55 63 2114 2122 B-clinical_variable
K 63 64 2122 2123 I-clinical_variable
> 65 66 2124 2125 O
20 66 68 2125 2127 B-lower_bound

Pioglitazone 0 12 2128 2140 B-treatment
is 13 15 2141 2143 O
not 16 19 2144 2147 O
recommended 20 31 2148 2159 O
in 32 34 2160 2162 O
patients 35 43 2163 2171 O
with 44 48 2172 2176 O
symptomatic 49 60 2177 2188 O
heart 61 66 2189 2194 B-chronic_disease
failure 67 74 2195 2202 I-chronic_disease

Postmenopausal 0 14 2203 2217 O
women 15 20 2218 2223 B-gender
who 21 24 2224 2227 O
have 25 29 2228 2232 O
not 30 33 2233 2236 O
undergone 34 43 2237 2246 O
a 44 45 2247 2248 O
DEXA 46 50 2249 2253 B-treatment
scan 51 55 2254 2258 I-treatment
over 56 60 2259 2263 O
the 61 64 2264 2267 O
last 65 69 2268 2272 O
year 70 74 2273 2277 O
will 75 79 2278 2282 O
undergo 80 87 2283 2290 O
a 88 89 2291 2292 O
DEXA 90 94 2293 2297 O
scan 95 99 2298 2302 O
at 100 102 2303 2305 O
screening 103 112 2306 2315 O

Postmenopausal 0 14 2316 2330 O
women 15 20 2331 2336 B-gender
who 21 24 2337 2340 O
have 25 29 2341 2345 O
undergone 30 39 2346 2355 O
a 40 41 2356 2357 O
DEXA 42 46 2358 2362 B-treatment
scan 47 51 2363 2367 I-treatment
during 52 58 2368 2374 O
the 59 62 2375 2378 O
last 63 67 2379 2383 O
year 68 72 2384 2388 O
and 73 76 2389 2392 O
have 77 81 2393 2397 O
a 82 83 2398 2399 O
T 84 85 2400 2401 B-clinical_variable
score 86 91 2402 2407 I-clinical_variable
better 92 98 2408 2414 O
than 99 103 2415 2419 O
-2.5 104 108 2420 2424 B-lower_bound
will 109 113 2425 2429 O
be 114 116 2430 2432 O
included 117 125 2433 2441 O
without 126 133 2442 2449 O
repeating 134 143 2450 2459 O
the 144 147 2460 2463 O
DEXA 148 152 2464 2468 O
scan 153 157 2469 2473 O
prior 158 163 2474 2479 O
to 164 166 2480 2482 O
enrollment 167 177 2483 2493 O

Postmenopausal 0 14 2494 2508 O
women 15 20 2509 2514 B-gender
who 21 24 2515 2518 O
have 25 29 2519 2523 O
undergone 30 39 2524 2533 O
a 40 41 2534 2535 O
DEXA 42 46 2536 2540 B-treatment
scan 47 51 2541 2545 I-treatment
during 52 58 2546 2552 O
the 59 62 2553 2556 O
last 63 67 2557 2561 O
year 68 72 2562 2566 O
, 72 73 2566 2567 O
have 74 78 2568 2572 O
a 79 80 2573 2574 O
T 81 82 2575 2576 B-clinical_variable
score 83 88 2577 2582 I-clinical_variable
worse 89 94 2583 2588 O
than 95 99 2589 2593 O
-2.5 100 104 2594 2598 B-lower_bound
and 105 108 2599 2602 O
are 109 112 2603 2606 O
not 113 116 2607 2610 O
on 117 119 2611 2613 O
bisphosphonates 120 135 2614 2629 B-treatment
or 136 138 2630 2632 O
other 139 144 2633 2638 O
appropriate 145 156 2639 2650 B-treatment
therapy 157 164 2651 2658 I-treatment

Pregnant 0 8 2659 2667 B-pregnancy

Prior 0 5 2668 2673 O
history 6 13 2674 2681 O
of 14 16 2682 2684 O
hemorrhagic 17 28 2685 2696 B-chronic_disease
cystitis 29 37 2697 2705 I-chronic_disease
or 38 40 2706 2708 O
hematuria 41 50 2709 2718 B-chronic_disease
while 51 56 2719 2724 O
receiving 57 66 2725 2734 O
cyclophosphamide 67 83 2735 2751 B-treatment
that 84 88 2752 2756 O
could 89 94 2757 2762 O
not 95 98 2763 2766 O
be 99 101 2767 2769 O
explained 102 111 2770 2779 O
by 112 114 2780 2782 O
other 115 120 2783 2788 O
causes 121 127 2789 2795 O

Receipt 0 7 2796 2803 O
of 8 10 2804 2806 O
any 11 14 2807 2810 O
investigational 15 30 2811 2826 B-treatment
new 31 34 2827 2830 I-treatment
drug 35 39 2831 2835 I-treatment
or 40 42 2836 2838 O
device 43 49 2839 2845 O
within 50 56 2846 2852 O
30 57 59 2853 2855 B-upper_bound
days 60 64 2856 2860 I-upper_bound
prior 65 70 2861 2866 I-upper_bound
to 71 73 2867 2869 O
screening 74 83 2870 2879 O
or 84 86 2880 2882 O
5 87 88 2883 2884 B-upper_bound
half 89 93 2885 2889 O
- 93 94 2889 2890 O
lives 94 99 2890 2895 O
of 100 102 2896 2898 O
the 103 106 2899 2902 O
agent 107 112 2903 2908 O
< 113 114 2909 2910 O
TAB>(whichever 114 128 2910 2924 O
is 129 131 2925 2927 O
longer 132 138 2928 2934 O
) 138 139 2934 2935 O
, 139 140 2935 2936 O
or 141 143 2937 2939 O
any 144 147 2940 2943 O
investigational 148 163 2944 2959 O
new 164 167 2960 2963 O
drug 168 172 2964 2968 O
with 173 177 2969 2973 O
known 178 183 2974 2979 O
long 184 188 2980 2984 O
- 188 189 2984 2985 O
term 189 193 2985 2989 O
effects 194 201 2990 2997 O

Serum 0 5 2998 3003 B-clinical_variable
hepatic 6 13 3004 3011 I-clinical_variable
transaminase 14 26 3012 3024 I-clinical_variable
levels 27 33 3025 3031 I-clinical_variable
> 34 35 3032 3033 O
2 36 37 3034 3035 B-lower_bound
times 38 43 3036 3041 I-lower_bound
upper 44 49 3042 3047 I-lower_bound
normal 50 56 3048 3054 I-lower_bound
limit 57 62 3055 3060 I-lower_bound
, 62 63 3060 3061 O
or 64 66 3062 3064 O
clinical 67 75 3065 3073 O
evidence 76 84 3074 3082 O
of 85 87 3083 3085 O
active 88 94 3086 3092 B-chronic_disease
liver 95 100 3093 3098 I-chronic_disease
disease 101 108 3099 3106 I-chronic_disease
at 109 111 3107 3109 O
screening 112 121 3110 3119 O

Significant 0 11 3120 3131 O
impairment 12 22 3132 3142 O
of 23 25 3143 3145 O
major 26 31 3146 3151 O
organ 32 37 3152 3157 O
function 38 46 3158 3166 O
( 47 48 3167 3168 O
lung 48 52 3168 3172 O
, 52 53 3172 3173 O
heart 54 59 3174 3179 O
, 59 60 3179 3180 O
liver 61 66 3181 3186 O
, 66 67 3186 3187 O
kidney 68 74 3188 3194 O
) 74 75 3194 3195 O
or 76 78 3196 3198 O
any 79 82 3199 3202 O
condition 83 92 3203 3212 O
that 93 97 3213 3217 O
, 97 98 3217 3218 O
in 99 101 3219 3221 O
the 102 105 3222 3225 O
opinion 106 113 3226 3233 O
of 114 116 3234 3236 O
the 117 120 3237 3240 O
Investigator 121 133 3241 3253 O
, 133 134 3253 3254 O
would 135 140 3255 3260 O
jeopardize 141 151 3261 3271 O
the 152 155 3272 3275 O
subject 156 163 3276 3283 O
s 164 165 3284 3285 O
safety 166 172 3286 3292 O
following 173 182 3293 3302 O
exposure 183 191 3303 3311 O
to 192 194 3312 3314 O
the 195 198 3315 3318 O
study 199 204 3319 3324 B-treatment
drug 205 209 3325 3329 I-treatment

These 0 5 3330 3335 O
subjects 6 14 3336 3344 O
would 15 20 3345 3350 O
be 21 23 3351 3353 O
eligible 24 32 3354 3362 O
to 33 35 3363 3365 O
participate 36 47 3366 3377 O
following 48 57 3378 3387 O
resolution 58 68 3388 3398 O
of 69 71 3399 3401 O
infection 72 81 3402 3411 O
before 82 88 3412 3418 O
Day 89 92 3419 3422 O
1 93 94 3423 3424 O
visit 95 100 3425 3430 O
within 101 107 3431 3437 O
the 108 111 3438 3441 O
allowed 112 119 3442 3449 O
46 120 122 3450 3452 B-upper_bound
days 123 127 3453 3457 I-upper_bound
screening 128 137 3458 3467 O
period 138 144 3468 3474 O

basal 0 5 3475 3480 B-cancer
cell 6 10 3481 3485 I-cancer
or 11 13 3486 3488 O
squamous 14 22 3489 3497 B-cancer
cell 23 27 3498 3502 I-cancer
carcinoma 28 37 3503 3512 I-cancer
of 38 40 3513 3515 I-cancer
the 41 44 3516 3519 I-cancer
skin 45 49 3520 3524 I-cancer
with 50 54 3525 3529 O
complete 55 63 3530 3538 O
excision 64 72 3539 3547 O
and 73 76 3548 3551 O
clear 77 82 3552 3557 O
borders 83 90 3558 3565 O
or 91 93 3566 3568 O
adequately 94 104 3569 3579 O
treated 105 112 3580 3587 O
in 113 115 3588 3590 O
situ 116 120 3591 3595 O
carcinoma 121 130 3596 3605 O
of 131 133 3606 3608 O
the 134 137 3609 3612 O
cervix 138 144 3613 3619 O

females 0 7 3620 3627 B-gender

lactating 0 9 3628 3637 O
women 10 15 3638 3643 B-gender

males 0 5 3644 3649 B-gender

patients 0 8 3650 3658 O
with 9 13 3659 3663 O
confirmed 14 23 3664 3673 O
non 24 27 3674 3677 B-chronic_disease
- 27 28 3677 3678 I-chronic_disease
alcoholic 28 37 3678 3687 I-chronic_disease
fatty 38 43 3688 3693 I-chronic_disease
liver 44 49 3694 3699 I-chronic_disease
disease 50 57 3700 3707 I-chronic_disease
( 58 59 3708 3709 I-chronic_disease
NAFLD 59 64 3709 3714 I-chronic_disease
) 64 65 3714 3715 I-chronic_disease
where 66 71 3716 3721 O
pioglitazone 72 84 3722 3734 B-treatment
has 85 88 3735 3738 O
been 89 93 3739 3743 O
reported 94 102 3744 3752 O
to 103 105 3753 3755 O
have 106 110 3756 3760 O
a 111 112 3761 3762 O
therapeutic 113 124 3763 3774 O
role 125 129 3775 3779 O

